A new Phase 2 clinical trial involving goserelin was listed as recruiting on October 1, 2026. The study, registered as NCT07460752, is titled "Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients."
According to the registry entry, the trial is currently in the recruiting phase. It is designated as a Phase 2 study. The trial focuses on an alternative injection site for goserelin acetate in premenopausal patients with hormone receptor positive breast cancer, specifically for ovarian function suppression.
No results have been posted for this trial at this time. The current listing reflects recruitment status only, and no efficacy or safety outcomes have been reported in the available data. Readers interested in enrollment criteria or further study details can consult the official clinical trial registry listing directly.
For more background on this compound, readers can refer to the goserelin overview page.